Amneal Pharmaceuticals (AMRX) Cost of Revenue (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Cost of Revenue of $402.4 million for Q1 2026, down 8.45% year-over-year from $439.5 million in Q1 2025, and down 22.18% quarter-over-quarter from $517.1 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Cost of Revenue (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Cost of Revenue history runs 10 years deep, the most recent figure standing at $402.4 million for Q1 2026.
- In Q1 2026, Cost of Revenue fell 8.45% year-over-year to $402.4 million; the TTM figure through Mar 2026 stood at $1.9 billion (up 4.26% YoY), while the FY2025 annual figure was $1.9 billion, up 7.44% from the prior year.
- Cost of Revenue for Q1 2026 stood at $402.4 million, down from $517.1 million in the prior quarter.
- The five-year high for Cost of Revenue was $517.1 million in Q4 2025, with the low at $764000.0 in Q1 2022.
- The 5-year median for Cost of Revenue is $421.1 million (2024), against an average of $356.0 million.
- The sharpest annual moves came in 2022 and 2023: Cost of Revenue plunged 78.67% in 2022, then surged 49553.66% in 2023.
- Amneal Pharmaceuticals' Cost of Revenue stood at $394.4 million in 2022, then gained by 8.31% to $427.2 million in 2023, then increased by 9.48% to $467.6 million in 2024, then increased by 10.58% to $517.1 million in 2025, then declined by 22.18% to $402.4 million in 2026.
- Business Quant data shows AMRX's Cost of Revenue at $402.4 million in Q1 2026, $517.1 million in Q4 2025, and $510.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Amneal Pharmaceuticals | 5.69 Bn | 5.56 Bn | 334.51 Mn | 461.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 461.69 Mn |
| Jun 30, 2026 | 461.69 Mn |
| Mar 31, 2026 | 402.41 Mn |
| Mar 31, 2026 | 402.41 Mn |
| Dec 31, 2025 | 517.13 Mn |
| Dec 31, 2025 | 517.13 Mn |
| Sep 30, 2025 | 510.54 Mn |
| Sep 30, 2025 | 510.54 Mn |
| Jun 30, 2025 | 438.26 Mn |
| Jun 30, 2025 | 438.26 Mn |
| Mar 31, 2025 | 439.53 Mn |
| Mar 31, 2025 | 439.53 Mn |
| Dec 31, 2024 | 467.65 Mn |
| Dec 31, 2024 | 467.65 Mn |
| Sep 30, 2024 | 432.91 Mn |
| Sep 30, 2024 | 432.91 Mn |
| Jun 30, 2024 | 451.83 Mn |
| Jun 30, 2024 | 451.83 Mn |
| Mar 31, 2024 | 421.13 Mn |
| Mar 31, 2024 | 421.13 Mn |